Transgene signs a Joint Venture agreement with Atral Cipan of Portugal involving the technology transfer of Tacrolimus by Transgene, followed by the manufacturing and global marketing in regulated and unregulated markets by Cipan.
Transgene Biotek becomes the world’s first company to create and launch 50% algal DHA oil, and 20% algal DHA powder. Sales of TrabiDHATM in both oil and powder forms continue to grow as market demand outstrips supply
Transgene Biotek finds partner to manufacture DHA in facility geared towards sales in regulated markets. Commercial operations from this new unit are expected to commence during the last quarter of the current financial year 2013-14.